Clinical Trial Detail

NCT ID NCT02900560
Title Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Translational Research in Oncology
Indications

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer

Therapies

Azacitidine + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.